The cost of multiple sclerosis in Australia

被引：24

作者：

Taylor, Bruce

McDonald, Elizabeth

Fantino, Bruno

Sedal, Les

MacDonnell, Richard

Pittas, Fotini

Groom, Trish

机构：

[1] Royal Hobart Hosp, Dept Neurol, Hobart, Tas, Australia

[2] Royal Hobart Hosp, MS Res Ctr, Hobart, Tas, Australia

[3] MS Soc Victoria, Melbourne, Vic, Australia

[4] Assoc Dev Informat Med, Lyon, France

[5] St Vincents Hosp, Dept Neurol, Melbourne, Vic, Australia

[6] Austin Repatriat Hosp, Dept Neurol, Melbourne, Vic, Australia

来源：

JOURNAL OF CLINICAL NEUROSCIENCE | 2007年 / 14卷 / 06期

关键词：

direct costs; indirect costs; interferon beta; multiple sclerosis; primary progressive; relapsing-remitting; secondary progressive;

D O I：

10.1016/j.jocn.2006.08.007

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis (MS) represents a significant economic burden both to the patient and to society. This study aims to provide information about direct and indirect costs of MS in Australia. Detailed questionnaires were completed for 100 patients over a 6-month period (12 months for hospitalization costs). Overall, the average annual direct and indirect costs per patient were AU$20 396 and AU$15 085, respectively. The greatest uses of resources were for immunomodulating drugs, consultations and district nursing. Various factors significantly increased overall direct costs, including secondary progressive MS, severe MS symptoms and higher Expanded Disability Status Scale scores. This study confirms that MS is a costly disease with a high economic burden on society. In order to minimize MS costs and improve quality of life, the ideal aim of MS treatment should be to stabilize patients on a low disability (low cost) level at an early stage of the disease utilising a cost-effective therapy. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：532 / 539

页数：8

共 23 条

[1] The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy [J].

Amato, MP ;

Battaglia, MA ;

Caputo, D ;

Fattore, G ;

Gerzeli, S ;

Pitaro, M ;

Reggio, A ;

Trojano, M .

JOURNAL OF NEUROLOGY, 2002, 249 (02) :152-163

[2] Economic consequences of multiple sclerosis for Canadians [J].

Asche, CV ;

Ho, E ;

Chan, B ;

Coyte, PC .

ACTA NEUROLOGICA SCANDINAVICA, 1997, 95 (05) :268-274

[3]

Auty A, 1998, CAN J NEUROL SCI, V25, P23

[4]

Battaglia MA, 2000, J NEUROVIROL, V6, pS191

[5]

BOURDETTE DN, 1993, ARCH PHYS MED REHAB, V74, P26

[6] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

[7] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].

Ebers, GC ;

Rice, G ;

Lesaux, J ;

Paty, D ;

Oger, J ;

Li, DKB ;

Beall, S ;

Devonshire, V ;

Hashimoto, S ;

Hooge, J ;

Kastrukoff, L ;

Krieger, C ;

Mezei, M ;

Seland, P ;

Vorobeychi, G ;

Morrison, W ;

Nelson, J ;

Freedman, MS ;

Chrisie, S ;

Nelson, R ;

Rabinovitch, H ;

Freedman, C ;

Hartung, HP ;

Rieckmann, P ;

Archelos, J ;

Jung, S ;

Weilbach, F ;

Flachenecke, P ;

Sauer, J ;

Hommes, O ;

Jongen, P ;

Brouwer, S ;

McLeod, J ;

Pollard, J ;

Ng, R ;

Sandberg-Wollheim, M ;

Källén, K ;

Nilsson, P ;

Ekberg, R ;

Lundgren, A ;

Jadbäck, G ;

Wikström, J ;

Multanen, J ;

Valjakka, M ;

Carton, H ;

Lissoir, F ;

Declerq, I ;

Vieren, M ;

Peeters, E ;

Dubois, B .

LANCET, 1998, 352 (9139) :1498-1504

[8]

Francis G, 2001, NEUROLOGY, V56, P1628

[9] The economics of multiple sclerosis - Distribution of costs and relationship to disease severity [J].

Grudzinski, AN ;

Hakim, Z ;

Cox, ER ;

Bootman, JL .

PHARMACOECONOMICS, 1999, 15 (03) :229-240

[10] Costs, quality of life and disease severity in multiple sclerosis:: a cross-sectional study in Sweden [J].

Henriksson, F ;

Fredrikson, S ;

Masterman, T ;

Jönsson, B .

EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (01) :27-35

← 1 2 3 →